Mersana Therapeutics Q2 2024 GAAP EPS $(0.20) Misses $(0.17) Estimate, Sales $2.293M Miss $8.722M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mersana Therapeutics (NASDAQ:MRSN) reported Q2 2024 GAAP EPS of $(0.20), missing the $(0.17) estimate by 17.65%. Sales were $2.293M, missing the $8.722M estimate by 73.71% and down 78.48% from $10.654M last year.
August 13, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Mersana Therapeutics reported Q2 2024 GAAP EPS of $(0.20), missing the $(0.17) estimate by 17.65%. Sales were $2.293M, missing the $8.722M estimate by 73.71% and down 78.48% from $10.654M last year.
The significant miss on both EPS and sales estimates, along with a substantial year-over-year decline in sales, is likely to negatively impact Mersana Therapeutics' stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100